A Study of the Effect and Safety of HS-10390 in the Treatment of Patients with Primary IgA Nephropathy

NCT06635772 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunoglobulin a Nephropathy

Interventions

DRUG: HS-10390
DRUG: Irbesartan

Sponsor

Hansoh BioMedical R&D Company